🇺🇸 FDA
Patent

US 11304996

Yeast-based immunotherapy and type I interferon sensitivity

granted A61KA61K2039/52A61K2039/57

Quick answer

US patent 11304996 (Yeast-based immunotherapy and type I interferon sensitivity) held by The Regents of the University of Colorado, a Body Corporate expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/52, A61K2039/57, A61K36/064, A61K39/0011